Kardigan (KARD) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kardigan is the larger company by market cap ($1.29 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KARD | REPL |
|---|---|---|
| Share price | $13.83 | $13.20 |
| Market cap | $1.29B | $1.24B |
| 1-day change | +2.52% | -0.38% |
| YTD return | — | +35.80% |
| 1-year return | — | +183.87% |
| 5-year return | — | -56.22% |
| EPS (TTM) | $-10.93 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.00 | $16.33 |
| 52-week low | $12.23 | $1.50 |
| Distance from 52-week high | -48.78% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +205.50% | +47.73% |
| Average volume | 483.42K | 4.17M |
| Shares outstanding | 93.50M | 94.22M |
| Employees | 241 | 465 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kardigan
KARD stock →Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
KARD vs REPL FAQ
Which is bigger, Kardigan or Replimune Group?
Kardigan (KARD) is larger, with a market capitalization of $1.29B compared with $1.24B for Replimune Group (REPL).
Are Kardigan and Replimune Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Kardigan and Biotechnology: Biological Products (No Diagnostic Substances) for Replimune Group.